Please wait while the formulary information is being retrieved.
VYLEESI (bremelanotide acetate)
- disorder of low sexual desire in premenopausal woman
1.75 mg/0.3 mL subcutaneous auto-injector
- Inject 1.75 mg by subcutaneous route once in the abdomen or thigh at least 45 minutes before sexual activity, not to exceed 1 dose in 24 hrs
Premenopausal acquired hypoactive sexual desire disorder
- Inject 1.75 mg by subcutaneous route once in the abdomen or thigh at least 45 minutes before sexual activity, not to exceed 1 dose in 24 hrs
- Inject 1.75 mg by subcutaneous route once in the abdomen or thigh at least 45 minutes before sexual activity, not to exceed 1 dose/24 hrs and 8 doses/month
- Inject 0.3 milliliter (1.75 mg) by subcutaneous route once in the abdomen or thigh at least 45 minutes before sexual activity, not to exceed 1 dose/24 hrs and 8 doses/month
- Inject 0.3 milliliter (1.75 mg) by subcutaneous route once in the abdomen or thigh at least 45 minutes before sexual activity, not to exceed 1 dose in 24 hrs
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Hypertension
Severe
Moderate
- None
VYLEESI (bremelanotide acetate)
- disorder of low sexual desire in premenopausal woman
- None
- Flushing
- Headache disorder
- Injection site sequelae
- Nausea
- Skin pigmentation enhancement
- Vomiting
More Frequent
Severe
Less Severe
- Hypertension
- Increased creatine kinase level
- Arthralgia
- Cough
- Diarrhea
- Dizziness
- Fatigue
- Myalgia
- Nasal congestion
- Pain
- Paresthesia
- Restless leg syndrome
- Rhinorrhea
- Upper abdominal pain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Hepatitis
Less Severe
- Flu-like symptoms
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Bremelanotide
Safety and effectiveness have not been established in pediatric patients.
- 1 Day – 18 Years
- Safety and effectiveness have not been established in pediatric patients.
Bremelanotide
- Severity Level:
2
- Additional Notes: Insufficient human data avail, mfg does not rec
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Bremelanotide
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Premenopausal acquired hypoactive sexual desire disorder | |
| F52.0 | Hypoactive sexual desire disorder |
| 0-9 | A-Z |
|---|---|
| F52.0 | Hypoactive sexual desire disorder |
Formulary Reference Tool